Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Kaisa Health Group Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -9.44%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Kaisa Health Group Holdings's 3-Year ROIIC % or its related term are showing as below:
HKSE:00876's 3-Year ROIIC % is ranked worse than 62.26% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 1.33
vs HKSE:00876: -9.44
Kaisa Health Group Holdings (HKSE:00876) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Kaisa Health Group Holdings 3-Year ROIIC % Related Terms
Kaisa Health Group Holdings 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00876 vs ISRG, BDX, RMD: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Kaisa Health Group Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaisa Health Group Holdings 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kaisa Health Group Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Kaisa Health Group Holdings's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -52.2171133 (Dec. 2025) - -64.618 (Dec. 2022) )
/
( 333.627 (Dec. 2025) - 465.012 (Dec. 2022) )
=
12.4008867
/
-131.385
=
-9.44%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Kaisa Health Group Holdings (HKSE:00876) has a 3-Year ROIIC % of -9.44 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Kaisa Health Group Holdings and its competitors. According to the industry distribution chart, Kaisa Health Group Holdings ranks #495 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 62.3%.
Is Kaisa Health Group Holdings' 3-Year ROIIC % too high?
Kaisa Health Group Holdings' current 3-Year ROIIC % is -9.44. Based on the distribution chart, Kaisa Health Group Holdings ranks #495 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kaisa Health Group Holdings has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kaisa Health Group Holdings' 3-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Kaisa Health Group Holdings ranks #495 out of 795 companies for 3-Year ROIIC %. This places Kaisa Health Group Holdings in the lower half of its industry. The industry median 3-Year ROIIC % is 1.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.33, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Kaisa Health Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaisa Health Group Holdings's current 3-Year ROIIC % is -9.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaisa Health Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kaisa Health Group Holdings (HKSE:00876) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.94, compared to a current price of HK$1.95 — trading 107.4% above its estimated fair value. The current 3-Year ROIIC % is -9.44. Kaisa Health Group Holdings' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Kaisa Health Group Holdings (HKSE:00876), the current 3-Year ROIIC % is -9.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaisa Health Group Holdings (HKSE:00876) Overvalued in 2026?
Based on GuruFocus' analysis, Kaisa Health Group Holdings stock appears to be overvalued.
The current stock price of HK$1.95 is trading 107.4% above its estimated GF Value™ of HK$0.94.
GuruFocus considers Kaisa Health Group Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00876:
3-Year ROIIC %: -9.44
GF Value™: HK$0.94 vs. price of HK$1.95 (107.4% above fair value)
No single metric tells the full story. See the HKSE:00876 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaisa Health Group Holdings Ltd, through its subsidiaries are mainly engaged in the manufacturing and sale of dental prosthetics and implant instruments, and the provision of sports rehabilitation services. The Group operates in two reportable segments: Dental Business, which consists of manufacturing and trading in dental products; and the Health Care Business, which provides services for sport rehabilitation, including postoperative rehabilitation, sports injury rehabilitation, chronic pain, scoliosis, deformity correction, other rehabilitation services, and health leisure business. The majority of its revenue is generated from the Dental business segment. Geographically, the Group generates maximum revenue from the People's Republic of China, and the rest from other countries.
37GF Score
Get the complete analysis for HKSE:00876
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00876 has been successfully added to your 
